Thiruvananthapuram, April 30: Kerala-based HLL Lifecare, a mini-ratna PSU, has floated wholly-owned subsidiary HLL Biotechltd to execute the Rs.594 crore Integrated Vaccine Complex (IVC) coming up in Tamil Nadu.
The first phase of IVC, which would come up at Chengalpattu in Tamil Nadu’s Kanchipuram district, will be completed within 36 months.
With an annual capacity of 585 million doses, it will manufacture pentavalent combination (DPT plus Hep B plus HIB), BCG, measles, Hepatitis B, human rabies, HIB and Japanese encephalitis vaccines.
“We have started onsite preliminary works at the 100 acre area. The project office has started functioning with sufficient staff, including the project officer,” said HLL chairman and managing director M. Ayyappan.
The project, cleared by the Cabinet Committee on Economic Affairs (CCEA) April 26, was announced in the previous budget and is intended to be a milestone in bolstering India’s vaccine security.